Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;113(3):283-289.
doi: 10.1111/ejh.14221. Epub 2024 May 6.

A prospective study of posttransplant cyclophosphamide for unrelated donor peripheral blood stem cell transplant with special attention to graft content and the impact of a higher γδ T cell dose

Chetan Jeurkar  1 , Benjamin Leiby  2 , Shaik Rashid  1 , Usama Gergis  1 , Dolores Grossso  1 , Matthew Carabasi  1 , Joanne Filicko-O'Hara  1 , William O'Hara  1 , Thomas Klumpp  1 , Pierluigi Porcu  1 , Neal Flomenberg  1 , John L Wagner  1
Affiliations

A prospective study of posttransplant cyclophosphamide for unrelated donor peripheral blood stem cell transplant with special attention to graft content and the impact of a higher γδ T cell dose

Chetan Jeurkar et al. Eur J Haematol. 2024 Sep.

Abstract

Posttransplant cyclophosphamide (PtCy) has been shown to decrease post-hematopoietic stem cell transplant acute and chronic graft-versus-host disease (GVHD). In this study, PtCy was used in 44 patients along with mycophenolate and tacrolimus with HLA matched (29) and mismatched (15) unrelated donors to determine the impact of graft content on outcome; thus, all patients had flow cytometric analysis of their graft content including the number of B cells, NK cells, and various T cell subsets. Higher γδ T cell dose was associated with the development of acute GVHD (p = .0038). For PtCy, further studies of the cell product along with further graft manipulation, such as selective γδ T cell depletion, could potentially improve outcomes.

Keywords: GVHD; posttransplant cyclophosphamide; γδ T cells.

PubMed Disclaimer

References

REFERENCES

    1. O'Donnell PV, Luznik L, Jones RJ, et al. Nonmyeloablative bone marrow transplantation from partially HLA‐mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8:377‐386.
    1. Luznik L, Bolanos‐Meade J, Zahurak M, et al. High‐dose cyclophosphamide as single agent, short‐course prophylaxis of graft‐versus‐host disease. Blood. 2010;115:3224‐3230.
    1. Broers AE, Jong CN, Bakunina K, et al. Posttransplant cyclophosphamide for prevention of graft‐versus‐host disease: the prospective randomized HOVON‐96 trial. Blood Adv. 2022;6:3378‐3885.
    1. Wachsmuth LP, Patterson MT, Eckhaus MA, Venzon DJ, Gress RE, Kanakry CG. Posttransplantation cyclophosphamide prevents graft‐versus‐host disease by inducing alloreactive T cell dysfunction and suppression. J Clin Invest. 2019;129:2357‐2373.
    1. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft‐versus‐host disease in human recipients of marrow from HL‐A‐matched sibling donors. Transplantation. 1974;18:295‐304.

MeSH terms

Substances